New CEO appointed for Arthritis Australia
The Board of Arthritis Australia is pleased to announce the appointment of Jonathan Smithers as our new Chief Executive Officer
Chair of the Board, Kristine Riethmiller said, “I know I speak for the entire Board when I say we are excited to have secured the services of an outstanding candidate. Jonathan brings a wealth of talent and experience to the role from the not-for-profit sector. His skills in organisational management and strategy coupled with high level stakeholder engagement will lead us to the next level as we move forward with implementation of the National Strategic Action Plan for Arthritis.”
“Jonathan has previous experience in senior roles, as the CEO of the Law Council of Australia and prior to that as the President of the Law Society of England & Wales. He will give us a fresh perspective on issues of critical importance to our work. In addition he has had over 30 years of legal practice, representing clients as consumers on a daily basis, so understands the importance of engaging with people living with arthritis to provide meaningful information, advocacy and support”
Jonathan said, “I am really looking forward to using my experience and skills in an organisation which already does great work to support people living with arthritis. I am eager to roll up my sleeves and work with the team.”
“With over four million Australians living with the condition in its many forms and having to cope with pain and disability, this role is critical in enabling Arthritis Australia to improve lives.”
Media Release – New CEO Appointed to Arthritis Australia
For enquiries:
Jonathan Smithers
CEO, Arthritis Australia
(02) 9518 4441
Mobile: 0488 011 063
Discover more...
-
Survey report on delays in receiving scripts and biologic medication
During 2020 and 2021, some people on biologic and targeted synthetic disease modifying anti-rheumatic drugs (b/tsDMARDs) for arthritis and other musculoskeletal conditions reported long delays...
-
Information about the abatacept (Orencia®) Shortage
There are currently shortages of abatacept (Orencia®) products in Australia. If you are currently taking abatacept (Orencia®), these shortages may affect your treatment.
-
The 1 in 7 Australians living with arthritis need more support – Arthritis Australia launches its election platform
During the 2022 federal election, Arthritis Australia sent a copy of our election platform and campaign flag to every federal MP and senator. Hundreds of...
Sign up to Arthritis Insights
Regular updates, news and research findings delivered to your inbox: